Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific ...

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...

PrimeGen US and DT Cloud Star Acquisition have entered a definitive merger agreement at an implied equity value of around $1.5bn.

Lilly anticipates revenue of between $80bn and $83bn in 2026 – a year that could see orforglipron enter the US market.

GSK is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.

Despite being saddled with tariffs and lagging behind China and the US, European sites offer biopharma suppliers a chance to diversify.

The guidance, which was published after the European market closed on 3 February, was punished by investors at market open.

SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...

Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts had expected as the drugmaker prepares for the loss of exclusivity of several ...

Relay Therapeutics has received the FDA BTD for zovegalisib, along with fulvestrant, for HR+/HER2- advanced breast cancer treatment.

Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.